| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
6.61(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,242,049 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
138,093 |
288,980 |
461,958 |
926,280 |
| Total Sell Value |
$8,135,395 |
$19,867,810 |
$25,677,895 |
$46,442,456 |
| Total People Sold |
7 |
8 |
8 |
12 |
| Total Sell Transactions |
11 |
21 |
41 |
87 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Morgans David J Jr |
SVP-Preclinical R&D |
• – – |
2007-09-28 |
4 |
AS |
$5.09 |
$25,450 |
D/D |
(5,000) |
84,500 |
|
- |
|
| Morgans David J Jr |
SVP-Preclinical R&D |
• – – |
2007-09-14 |
4 |
AS |
$4.75 |
$23,750 |
D/D |
(5,000) |
89,500 |
|
- |
|
| Morgans David J Jr |
SVP-Preclinical R&D |
• – – |
2007-09-14 |
4 |
OE |
$1.20 |
$38,400 |
D/D |
32,000 |
94,500 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2007-09-11 |
4 |
GD |
$0.00 |
$0 |
I/I |
4,000 |
192,550 |
|
- |
|
| Spudich James A |
Director |
– • – |
2007-09-05 |
4 |
AS |
$4.95 |
$14,856 |
D/D |
(3,000) |
198,600 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-08-30 |
4 |
AS |
$5.11 |
$33,460 |
D/D |
(6,548) |
38,720 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-08-30 |
4 |
OE |
$0.58 |
$12,865 |
D/D |
6,548 |
45,105 |
|
- |
|
| Dow Stephen M |
Director |
– • – |
2007-08-17 |
4 |
B |
$5.07 |
$101,420 |
I/I |
20,000 |
145,000 |
2.1 |
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-08-15 |
4 |
AS |
$5.04 |
$32,745 |
D/D |
(6,497) |
38,720 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-08-15 |
4 |
OE |
$0.58 |
$3,768 |
D/D |
6,497 |
45,217 |
|
- |
|
| Trautman Jay K |
VP, Discovery Research |
• – – |
2007-08-10 |
4 |
OE |
$1.20 |
$36,000 |
D/D |
30,000 |
47,896 |
|
- |
|
| Spudich James A |
Director |
– • – |
2007-08-02 |
4 |
AS |
$5.23 |
$15,690 |
D/D |
(3,000) |
201,600 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2007-08-01 |
4 |
AS |
$5.00 |
$35,000 |
D/D |
(7,000) |
0 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2007-08-01 |
4 |
OE |
$1.20 |
$8,400 |
D/D |
7,000 |
7,000 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-07-31 |
4 |
AS |
$5.00 |
$31,970 |
D/D |
(6,394) |
38,720 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-07-31 |
4 |
OE |
$0.58 |
$155 |
D/D |
267 |
45,114 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-07-16 |
4 |
AS |
$5.47 |
$33,940 |
D/D |
(6,188) |
44,847 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-07-16 |
4 |
OE |
$0.58 |
$35 |
D/D |
60 |
51,035 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2007-07-06 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,600 |
196,550 |
|
- |
|
| Spudich James A |
Director |
– • – |
2007-07-03 |
4 |
AS |
$5.68 |
$17,058 |
D/D |
(3,000) |
204,600 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2007-07-02 |
4 |
AS |
$5.70 |
$39,904 |
D/D |
(7,000) |
0 |
|
- |
|
| Sabry James H |
Executive Chairman |
• • – |
2007-07-02 |
4 |
OE |
$1.20 |
$8,400 |
D/D |
7,000 |
7,000 |
|
- |
|
| Morgans David J Jr |
SVP-Preclinical R&D |
• – – |
2007-06-29 |
4 |
AS |
$6.00 |
$30,000 |
D/D |
(5,000) |
62,500 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2007-06-29 |
4 |
AS |
$5.86 |
$33,867 |
D/D |
(5,775) |
50,975 |
|
- |
|
| Morgans David J Jr |
SVP-Preclinical R&D |
• – – |
2007-06-15 |
4 |
AS |
$6.46 |
$32,300 |
D/D |
(5,000) |
67,500 |
|
- |
|
1115 Records found
|
|
Page 37 of 45 |
|
|
0.38 (0.71%) 
